Sigesbeckia – herbal ingredient traditionally used for managing pain

Phynova Joint and Muscle Pain Relief Tablets contain the active ingredient, Sigesbeckia extract. Sigesbeckia was first licensed by a Western health authority in 2015, when the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), granted a THR medicine licence to Phynova Joint and Muscle Pain Relief Tablets. Sigesbeckia has a long history of safe use for relieving a wide range of musculoskeletal pains all around the world, with the first recorded use dating back in 659AD in China. For the past 30 years it has been used in Europe as in traditional herbal medicines, which was the basis for demonstrating its efficacy as a registered Traditional Herbal Medicine for the relief of backache, rheumatic pain, joint and muscle pain, as well as minor sports injuries (i.e. based exclusively on long-standing use as a traditional medicine).

What are the benefits of using Sigesbeckia?

Daily joint and muscle relief that is gentle on the stomach and can be used with other pain relief medication

Contains 500mg Sigesbeckia, a medicinal plant used to relieve rheumatic and joint pain with no known side effects

Convenient tablet that can be taken with or without food – one tablet in the morning, one in the evening

Suitable for daily use and non-addictive. It is recommended that they are taken regularly

What is a THR?

A Traditional Herbal Registration or THR is a specific type of over-the-counter medicine licence that is granted to a medicinal product where the active ingredient is a plant or herb. Only products that satisfy the stringent safety and quality requirements of the UK’s medicine regulatory authority, the Medicines & Healthcare products Regulatory Agency (MHRA), are granted a THR and this licence ensures that the product you buy is of pharmaceutical quality and meets strict safety standards.  THRs do not have to provide clinical trial evidence of efficacy on the finished product, rather they need to demonstrate the efficacy of the herbal medicine through 30-years of use for the medical condition as well as any bibliographic clinical trial evidence.

Only buy medicines from websites displaying the European Common Logo.

This system was introduced in 2013 by the European Council in the Falsified Medicines Directive. The Directive introduced harmonised measures to ensure medicines are safe and that active pharmaceutical ingredients are tightly controlled to prevent counterfeit medicines. The common logo should be displayed on every page of legally operating pharmacies and retailer websites.